RxDoctor Payments Data

Tracy Walker

Family · Syracuse, NYNPI 1740402379

Payments from drug & device makers

$2,644in general payments, 2019–2025

Across 122 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$491
  • AbbVie$444
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$295
  • Aimmune Therapeutics, Inc.$167
  • Johnson & Johnson$149
  • Madrigal Pharmaceuticals$138
  • plus $960 from 16 others

What the payments were for

  • Food & beverage$2,644100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,644 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$46,140
Medicare patients
354
Services billed
465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin28$102,729
CreonLipase/Protease/Amylase28$96,322
Humira(Cf) PenAdalimumab14$95,362
LinzessLinaclotide68$69,826
Mesalamine32$14,142
ClenpiqSod Picosulf/Mag Ox/Citric Ac45$7,603
Mesalamine ErMesalamine19$6,767
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C41$5,609
SutabSod Sulf/Pot Chloride/Mag Sulf28$4,430
Lubiprostone19$4,429
Famotidine293$3,813
Pantoprazole Sodium201$2,792
Esomeprazole Magnesium41$2,787
Omeprazole254$2,702
Ursodiol12$2,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$444$166,14896 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$295$108,33869 claims
Ferring Pharmaceuticals Inc.Clenpiq$65$7,60345 claims
Braintree Laboratories, Inc.Sutab$52$4,43028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →